<DOC>
	<DOCNO>NCT01081938</DOCNO>
	<brief_summary>Primary Objective : 1- Proportion patient mean daily glycemia &lt; 140mg/dL period 7 day treatment glargine plus supplemental glulisine versus patient glulisine slide scale . Secondary Objective : 1 . Incidence moderate hyperglycemia ( &gt; 140mg/dL ) treatment period . 2 . Incidence hypoglycemia ( &lt; 60mg/dL &lt; 40mg/dL ) treatment period . 3 . Incidence severe hyperglycemia ( &gt; 400mg/dL ) treatment period . 4 . Total dose insulin correction dose group .</brief_summary>
	<brief_title>Insulin Glargine Diabetes Metabolism ( DM ) Type II Patients Under Enteral Nutrition</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Men woman type 2 diabetes need enteral nutrition carbohydrate content . Glycemia &gt; 140mg/dL &lt; 400mg/dL admission ward . Informed consent ( patient legally authorize representative ) Exclusion criterion : Hypersensibility insulin glargine glulisine , component insulin formulation . Use investigational medication last 12 month use investigational insulin preparation last 4 month . History diabetic ketoacidosis hyperosmolar hyperglycaemic state ketonuria . Subjects condition expect need surgery intensive care unit ( ICU ) admission base discussion treatment team attend physician . Pregnancy . Severe hepatic disease active hepatitis . Cardiac failure class III IV ( Classification de la New York Heart Association : NYHA ) . Diagnosed advanced autonomic neuropathy . Diagnosed cancer . Active infection . Current therapy steroid . Patients recognize suspected endocrine disorder associate increased insulin resistance , acromegaly , hyperthyroidism . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>